Captrust Financial Advisors Purchases 86 Shares of Insulet Co. (NASDAQ:PODD)

Captrust Financial Advisors grew its holdings in Insulet Co. (NASDAQ:PODD) by 5.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,760 shares of the medical instruments supplier’s stock after purchasing an additional 86 shares during the quarter. Captrust Financial Advisors’ holdings in Insulet were worth $410,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. QRG Capital Management Inc. bought a new position in Insulet in the third quarter valued at approximately $297,000. Fisher Asset Management LLC boosted its position in shares of Insulet by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after purchasing an additional 3,113 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Insulet during the second quarter worth $554,000. GSA Capital Partners LLP bought a new stake in Insulet in the third quarter valued at about $1,017,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in Insulet by 3.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 156,326 shares of the medical instruments supplier’s stock valued at $36,385,000 after purchasing an additional 5,226 shares during the last quarter.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on PODD. Barclays raised their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Wells Fargo & Company boosted their price objective on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a report on Wednesday. Raymond James increased their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Sanford C. Bernstein assumed coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. Finally, Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $267.44.

Insulet Stock Down 0.9 %

NASDAQ:PODD opened at $269.34 on Friday. The company has a market cap of $18.89 billion, a PE ratio of 46.12, a PEG ratio of 4.18 and a beta of 1.21. The stock has a 50-day simple moving average of $251.37 and a 200 day simple moving average of $220.02. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.77.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.